Exelixis Inc Payments to Acquire Restricted Certificates of Deposit
Exelixis Inc (EXEL) reported Payments to Acquire Restricted Certificates of Deposit of $1.50 million for the 3-month period ending 2016-06-30, per its 10-Q filed 2016-08-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit · last filed 2016-08-03
- Exelixis Inc payments to acquire restricted certificates of deposit for the quarter ending 2016-06-30 was $1.50M.
| Period end | Payments to Acquire Restricted Certificates of Deposit 3 month |
|---|---|
| 2016-06-30 | $1.50M 10-Q · filed 2016-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |